FindTrial
Sign In

A clinical trial to learn about the effects of 225Ac-ETN029 in people with advanced solid tumors

Status
Not yet recruiting
Phases
Phase 1
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-519111-34-00
Enrollment
37
Registered
2026-09-08
Start date
Unknown
Completion date
Unknown
Last updated
2026-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), Large Cell Neuroendocrine Carcinoma (LCNEC) of the lung, Neuroendocrine Prostate Cancer (NEPC), Small Cell Lung Cancer (SCLC)

Interventions

None listed

Sponsors

Novartis Pharma AG
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Outcome results

None listed

Source: EU CTIS · Data processed: Sep 10, 2026